HIV-1 and the self-nonself connection: How to sleep with the enemy and be much better off

AIDS Reviews

Volumn 10, Issue 3, 2008, Pages 162-171

  Lopalco, Lucia ^a   Burastero, Samuel E ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Anti cell antibodies; Autoimmunity; Cross reactive antibodies; HIV; Natural immunity; Natural resistance

Indexed keywords

ANTIRETROVIRUS AGENT; AUTOANTIGEN; CD4 ANTIGEN; CELL ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; HLA ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MOLECULAR MARKER; NEUTRALIZING ANTIBODY;

ALLOIMMUNITY; ANTIBODY TITER; ANTIGEN RECOGNITION; AUTOIMMUNITY; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CORRELATION ANALYSIS; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFECTION RESISTANCE; INFLAMMATION; MOLECULAR MIMICRY; NONHUMAN; RETROVIRUS; REVIEW; T LYMPHOCYTE; VIRUS ENVELOPE;

ANIMALS; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNITY; CROSS REACTIONS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, NATURAL; MOLECULAR MIMICRY;

EID: 55049092133     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. Lane H, Fauci A. Immunologic abnormalities in AIDS. Annu Rev Immunol. 1985;3:477-500.
2. Moog C, Fleury H, Pellegrin I, Kim A, Aubertin A. Autologous and heterologous neutralizing antibody responses following initial seroconversion in HIV-1-infected individuals. J Virol. 1997;71:3734-41.
3. Pilgrim A, Pantaleo G, Cohen O, et al. Neutralizing antibody responses to HIV-1 in primary infection and long-term-nonprogressive infection. J Infect Dis. 1997;176:924-32.
4. Haynes B, Moody M, Verkoczy L, Kelsoe G, Alam S. Antibody polyspecificity and neutralization of HIV-1: a hypothesis. Hum Antibodies. 2005;14:59-67.
5. Alam S, McAdams M, Boren D, et al. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human MAb 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J Immunol. 2007;178:4424-35.
6. Haynes B, Shattock R. Critical issues in mucosal immunity for HIV-1 vaccine development. J Allergy Clin Immunol. 2008;122:3-9.
7. Home J, Fitzharris T, Youngbar P, Matthews D, Rackowski J, Radka S. Nonrandom association of cellular antigens with HTLV-III virions. Hum Immunol. 1987;18:39-52.
8. Zandman-Goddard G, Shoenfeld Y. HIV and autoimmunity. Autoimmun Rev. 2002;1:329-37.
9. Borghi M, De Santis C, Barcellini W, et al. Autoantibodies against beta 2-microglobulin-free HLA antigens in AIDS patients. J Acquir Immune Defic Syndr. 1993;16:1114-9.
10. de Santis C, Lopalco L, Robbioni P, et al. Human antibodies to immunodominant C5 region of HIV-1 gp120 cross-react with HLA class 1 on activated cells. AIDS Res Hum Retroviruses. 1994;10:157-62.
11. Burastero S, Gaffi D, Lopalco L, et al, Autoantibodies to CD4 in HIV type 1-exposed seronegative individuals. AIDS Res Hum Retroviruses. 1996;12:273-80.
12. Barassi C, Soprana E, Pastori C, et al. Induction of murine mucosal CCR5-reactive antibodies as an anti-HIV strategy. J Virol. 2005;79: 6848-58.
13. Bouhlal H, Latry V, Requena M, et al. Natural antibodies to CCR5 from breast milk block infection of macrophages and dendritic cells with primary R5-tropic HIV-1. J Immunol. 2005;174:7202-9.
14. Haynes B, Fleming J, St Clair E, et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science. 2005;308:1906-8.
15. Scherer E, Zwick M, Teyton L, Burton D. Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity. AIDS. 2007;21:2131-9.
16. Vcelar B, Stiegler G, Wolf HM, et al. Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data. AIDS. 2007; 21:2160-70.
17. Kwong P, Wyatt R, Robinson J, Sweet R, Sodroski J, Hendrickson W. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 1998; 393:648-59.
18. Weissenhorn W, Dessen A, Harrison S, Skehel J, Wiley D. Atomic structure of the ectodomain from HIV-1 gp41. Nature. 1997; 387:426-30.
19. Wei X, Decker J, Wang S, et al. Antibody neutralization and escape by HIV-1. Nature. 2003;422:307-12.
20. Kwong P, Doyle M, Casper D, et al. HIV-1 evades antibody mediated neutralization through conformational masking of receptor binding sites. Nature. 2002;422:307-12.
21. Sun Z, Oh K, Kim M, et al. HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity. 2008;28:52-63.
22. Calarese D, Scanlan C, Zwick M, et al. Antibody domain exchange is an immunologic solution to carbohydrate cluster recognition. Science. 2003;300:2065-71.
23. Scanlan C, Ritchie G, Baruah K, et al. Inhibition of mammalian glycan biosynthesis produces nonself antigens for a broadly neutralizing, HIV-1 specific antibody. J Mol Bio. 2007;372:16-22.
24. Crooks E, Moore P, Franti M, et al. A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology. 2007;366:245-62.
25. Alam S, Scearce R, Parks R, et al. HIV-1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection. J Virol. 2008;82:115-25.
26. Diamond B. Autoimmunity. Immunot Rev. 2005;204:5-8.
27. Starr T, Jameson S, Hogquist K. Positive and negative selection of T-cells. Annu Rev Immunol. 2003;21:139-76.
28. Douek D, McFarland R, Keiser P, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature. 1998; 396:690-5.
29. + T-cells. Nature, 2005;434:1148-52.
30. Silvestri G, Paiardini M, Pandrea I, Lederman M, Sodora D. Understanding the benign nature of SIV infection in natural hosts. J Clin Invest. 2007;117:3148-54.
31. Rawson P, Molette C, Videtta M, et al. Cross-presentation of caspase-cleaved apoptotic self antigens in HIV infection. Nat Med. 2007; 13:1431-9.
32. Lopalco L. Humoral immunity in HIV-1 exposure: cause or effect of HIV resistance? Curr HIV Res. 2004;2:127-39.
33. Beretta A, Weiss S, Rappocciolo G, et al. HIV-seronegative injection drug users at risk for HIV exposure have antibodies to HLA class I antigens and T-cells specific for HIV envelope. J Infect Dis. 1996; 173:472-6.
34. Lopalco L, Barassi C, Pastori C, et al. CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 in vitro. J Immunol. 2000;164:3426-33.
35. Barassi C, Lazzarin A, Lopalco L. CCR5-specific mucosal IgA in saliva and genital fluids of HIV-exposed seronegative subjects. Blood. 2004;104:2205-6.
36. Furci L, Beretta A, Siccardi A, et al. HIV-1 glycoprotein 120-specific T lymphocytes provide intermolecular help for anti-CD4 autoantibody production in exposed uninfected subjects. AIDS Res Hum Retroviruses. 1997;13:1461-9.
37. Clerici M, Butto S, Lukwiya M, et al. Immune activation in Africa is environmentally driven and is associated with upregulation of CCR5. Italian-Ugandan AIDS Project. AIDS. 2000;14:2083-92.
38. Heredia A, Gilliam B, DeVico A, et al. CCR5 density levels on primary CD4 T-cells impact the replication and enfuvirtide susceptibility of R5 HIV-1. AIDS. 2007;21:1317-22.
39. Ketas T, Kuhmann S, Palmer A, et al. Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands. Virology. 2007; 364:281-90.
40. Lin Y, Mettling C, Portales P, Reynes J, Clot J, Corbeau P. Cell surface CCR5 density determines the post entry efficiency of R5 HIV-1 infection. Proc Natl Acad Sci USA. 2002;99:15590-5.
41. Dolan M, Kulkarni H, Camargo J, et al. CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nat Immunol. 2007;8:1324-36.
42. Lopalco L. Magnani Z, Confetti C, et al. Anti-CD4 antibodies in exposed seronegative adults and in newborns of HIV-1 seropositive mothers: a follow-up study. AIDS Res Hum Retrovinuses. 1999;15: 1079-85.
43. MacDonald K, Embree J, Njenga S, et al. Mother-child class I HLA concordance increases perinatal HIV-1 transmission. J Infect Dis. 1998;177:551-6.
44. Peters B, Whittall T, Babaahmady K, Gray K, Vaughan R, Lehner T. Effect of heterosexual intercourse on mucosal alloimmunisation and resistance to HIV-1 infection. Lancet. 2004;363:518-24.
45. Jennes W, Kestens L. Unprotected sex and alloimmune activation. Lancet, 2004;363:1474; author reply 1475.
46. Quayle A, Fidel P, Rosenberg E. Sex, alloimmunisation, and susceptibility to HIV infection. Lancet. 2004;363:503-4.
47. Ansari A. Autoimmunity, anergy, lentiviral immunity and disease. Autoimmun Rev. 2004;3:530-40.
48. Nakagawa K, Harrison L. The potential roles of endogenous retroviruses in autoimmunity. Immunol Rev. 1996;152:193-236.
49. Taruscio D, Mantovani A. Factors regulating endogenous retroviral sequences in human and mouse. Cytogenet Genome Res. 2004; 105:351-62.
50. Krieg A, Gourley M, Perl A. Endogenous retroviruses: potential etiologic agents in autommunity. Faseb J. 1992;6:2537-44.
51. Kurth R, Teich N, Weiss R, Oliver R. Natural human antibodies reactive with primate type-C viral antigens. Proc Natl Acad Sci USA. 1977; 74:1237-41.
52. Blomberg J, Nived O, Pipkorn R, Bengtsson A, Erlinge D, Sturfelt G. Increased antiretroviral antibody reactivity in sera from a defined population of patients with SLE. Correlation with autoantibodies and clinical manifestations. Arthritis Rheum. 1994;37:57-66.
53. Buller R, Van Zant G, Eldridge P, Portis J. A population of murine hematopoietic progenitors expresses an endogenous retroviral gp70 linked to the Rmcf gene and associated with resistance to erythroleukemia. J Exp Med. 1989;169:865-80.
54. Pascual M, Martin J, Nieto A, et al. Distribution of HERV-LTR elements in the 5′-flanking region of HLA-DQB1 and association with autoimmunity. Immunogenetics. 2001;53:114-8.
55. Panoutsakopoulou V, Cantor H. On the relationship between viral infection and autoimmunity. J Autoimmun 2001;16:341-5.
56. Sabbaga J, Pankewycz O, Lufft V, Schwartz R, Madaio M. Cross-reactivity distinguishes serum and nephritogenic anti-DNA antibodies in human lupus from their natural counterparts in normal serum. J Autoimmun. 1990;3:215-35.
57. Chen Q, Mackay I, Fida S, Myers M, Rowley M. Natural and disease associated autoantibodies to the autoantigen, dihydrolipoamide acetyltransferase, recognize different epitopes. J Autoimmun. 1998; 11:151-61.
58. Petrovas C, Vlachoyiannopoulos P, Kordossis T, Moutsopoulos H. Anti-phospholipid antibodies in HIV infection and SLE with or without anti-phospholipid syndrome: comparisons of phospholipid specificity, avidity and reactivity with beta2-GPI. J Autoimmun. 1999; 13:347-55.
59. Raulin J. HIV and host cell lipids. Interesting pathways in research for a new HIV therapy. Prog Lipid Res. 2002;41:27-65.
60. Root-Bernstein R. Antigenic complementarity between HIV and other AIDS-associated infections results in idiotype-antiidiotype antibody complexes that cross react with lymphocyte proteins. Vaccine. 2005; 23:2160-3.
61. Lake D, Schluter S, Wang E, Bernstein R, Edmundson A, Marchalonis J. Autoantibodies to the alpha/beta T-cell receptors in HIV infection: dysregulation and mimicry. Proc Natl Acad Sci USA. 1994; 91:10849-53.
62. Golding H, Robey F, Gates F, et al. Identification of homologous regions in HIV-1 gp41 and human MHC class II beta 1 domain. I. MAb against the gp41 derived peptide and patients' sera react with native HLA class II antigens, suggesting a role for autoimmunity in the pathogenesis of AIDS. J Exp Med. 1988;167:914-23.
63. Fraziano M, Montesano C, Lombardi V, et al. Epitope specificity of anti-HIV antibodies in human and murine autoimmune diseases. AIDS Res Hum Retroviruses. 1996;12:491-6.
64. Lopalco L, De Santis C, Meneveri R, et al. HIV-1 gp120 C5 region mimics the HLA class I alpha 1 peptide-binding domain. Eur J Immunol. 1993;23:2016-21.
65. Cadogan M, Austen B, Heeney J, Dalgleish A. HLA homology within the C5 domain promotes peptide binding by HIV-1 gp120. AIDS Res Hum Retroviruses. 2008;24:845-55.
66. Palker T, Matthews T, Clark M. et al. A conserved region at the COOH terminus of HIV gp120 envelope protein contains an immunodominant epitope. Proc Natl Acad Sci USA. 1987; 84:2479-83.
67. Wong M, Warren R, Anderson S, et al. Longitudinal analysis of the humoral immune response to HIV-1 gp160 epitopes in rapidly progressing and non-progressing HIV-1-infected subjects. J Infect Dis. 1993;168:1523-7.
68. Meerloo T, Sheikh M, Bloem AC, et al. Host cell membrane proteins on HIV-1 after in vitro infection of H9 cells and blood mononuclear cells. An immuno-electron microscopic study. J Gen Virol. 1993; 74:129-35.
69. Nguyen D, Hildreth J. Evidence for budding of HIV-1 selectively from glycolipid-enriched membrane lipid rafts. J Virol. 2000; 74:3264-72.
70. Cantin R, Fortin J, Lamontagne G, Tremblay M. The presence of host-derived HLA-DR1 on HIV-1 increases viral infectivity. J Virol. 1997;71:1922-30.
71. Percherancier Y, Lagane B, Planchenault T, et al. HIV-1 entry into T-cells is not dependent on CD4 and CCR5 localization to sphingolipid enriched, detergent-resistant, raft membrane domains. J Biol Chem. 2003;278:3153-61.
72. Morita E, Sundquist W. Retrovirus budding. Annu Rev Cell Dev Biol. 2004;20:395-425.
73. Thery C, Regnault A, Garin J, et al. Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. J Cell Biol. 1999;147:599-610.
74. Verani A, Gras G. Pancino G. Macrophages and HIV-1: dangerous liaisons. Mol Immunol. 2005;42:195-212.
75. Gould S, Booth A, Hildreth J. The Trojan exosome hypothesis. Proc Natl Acad Sci USA. 2003;100:10592-7.
76. Kunkel SL, Godessart N. Chemokines in autoimmunity: from pathology to therapeutics. Autoimmun Rev. 2002;1:313-20.
77. Wang Y, Underwood J, Vaughan R. Harmer A, Doyle C, Lehner T. Allo-immunization elicits CCR5 antibodies, SDF-1 chemokines, and CD8-suppressor factors that inhibit transmission of R5 and X4 HIV-1 in women. Clin Exp Immunol. 2002;129:493-501.
78. Ditzel H, Rosenkilde M, Garred P, et al. The CCR5 receptor acts as an alloantigen in CCR5Δ32 homozygous individuals: identification of chemokine and HIV-1-blocking human antibodies. Proc Natl Acad Sci USA. 1998;95:5241-5.
79. Trkola A, Ketas T, Nagashima K, et al. Potent, broad-spectrum inhibition of HIV-1 by the CCR5 MAb PRO 140. J Virol. 2001; 75:579-88.
80. Lopalco L, Barassi C, Paolucci C, et al. Predictive value of anti-cell and anti-HIV humoral responses in HIV-1-exposed seronegative cohorts of European and Asian origin. J Gen Virol. 2005; 86:339-48.
81. Pastori C, Weiser B, Barassi C, et al. Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression. Blood. 2006; 107:4825-33.
82. Russo S, Lopalco L. Is autoimmunity a component of natural immunity to HIV? Curr HIV Res. 2006;4:177-90.
83. Nemazee D. Receptor editing in lymphocyte development and central tolerance. Nat Rev Immunol. 2006;6:728-40.
84. Trkola A, Kuster H, Rusert P, et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med. 2005;11:615-22.
85. Julg B, Goebel F. What's new in HIV/AIDS? Neutralizing HIV antibodies: do they really protect? Infection. 2005;33:405-7.
86. Trkola A, Kuster H, Rusert P, et al. In vivo efficacy of HIV neutralizing antibodies: estimates for protective titers. J Virol. 2008;82:1591-9.
87. Zwick M, Jensen R, Church S, et al. Anti-HIV-1 antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J Virol. 2005;79:1252-61.
88. Law M, Cardoso R, Wilson I. Burton D. Antigenic and immunogenic study of membrane-proximal external region-grafted gp 120 antigens by a DNA prime-protein boost immunization strategy. J Virol. 2007;81:4272-85.
89. Montero M, van Houten N, Wang X, Scott J. The membrane proximal external region of the HIV-1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev. 2008;72:54-84.
90. Cardoso R, Zwick M, Stanfield R, et al. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity. 2005; 22:163-73.
91. Barbas S, Ditzel H, Salonen E, Yang W, Silverman G, Burton D. Human autoantibody recognition of DNA. Proc Natl Acad Sci USA. 1995; 92:2529-33.
92. Vijh-Warrier S, Murphy E. Yokoyama I, Tilley S. Characterization of the variable regions of a chimpanzee MAb with potent neutralizing activity against HIV-1. Mol Immunol. 1995;32:1081-92.
93. Wang Q, Wang H, Blalock E, Muller S, Kohler H. Identification of antidiotypic peptice recognized by autoantibodies in HIV-1-infected individuals. J Clin Invest. 1995;96:775-80.
94. + B-cells from a rheumatoid arthritis patient. Int Immunol. 1991;3:865-75.
95. Johnston M, Fauci A. An HIV vaccine-evolving concepts. N Engl J Med. 2007;356:2073-81.
96. Rosenfeld C, Calabrese L. Progression of autoimmune thyroiditis in an HIV-infected woman on HAART. AIDS Read. 1999;9:393-4.
97. Jubault V, Penfornis A, Schillo F, et al. Sequential occurrence of thyroid autoantibodies and Graves' disease after immune restoration in severely immunocompromised HIV-1 infected patients. J Clin Endocrinol Metab. 2000;85:4254-7.
98. Bogers W, Bergmeier L, Oostermeijer H, et al. CCR5 targeted SIV vaccination strategy preventing or inhibiting SIV infection, Vaccine. 2004;22:2974-84.
99. Chackerian B, Lenz P, Lowy D, Schiller J. Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J Immunol. 2002:169:6120-6.
100. Zuber B, Hinkula J, Vodros D, et al. Induction of immune responses and break of tolerance by DNA against the HIV-1 coreceptor CCR5 but no protection from SIVsm challenge. Virology. 2000; 278:400-11.
101. Leith J, Clark D, Matthews T, et al. Assessing human alloimmunization as a strategy for inducing HIV type 1 neutralizing anti-HLA responses. AIDS Res Hum Retroviruses. 2003;19:957-65.
102. Bourinbaiar A, Abulafia-Lapid R. Clinical experience with therapeutic AIDS vaccines. Expert Rev Vaccines. 2005;4:289-304.
103. Crabb C. GlaxoSmithKline ends aplaviroc trials. AIDS. 2006;20:641.
104. Rivero A. Mira J, Pineda J, Liver toxicity induced by nonnucleoside reverse transcriptase inhibitors. J Antimicrob Chemother. 2007; 59:342-6.
105. Miyasawa M, Lopalco L, Mazzotta F, Locaputo S, Veas F, Clerici M, for the ESN group. Factors Modulating the Susceptibility to HIV in Humans: the "Immunologic Advantage" of HIV-Exposed Seronegative Individuals. AIDS. 2008; [in press].